Cognitive Peptides Cluster
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
How can it help me?
These three — Dihexa, Pinealon, and Cortagen — are second-tier cognitive peptides: interesting, but without the evidence depth of Semax or Selank. We lead with the honest part: Dihexa's foundational paper has a major retraction. Pinealon and Cortagen come from the Russian “Khavinson” short-peptide tradition — a 50-year research program that's heterodox by Western standards but internally consistent.
Honest read: treat this as a reference on what these are and how strong (or thin) the evidence really is — not as a recommendation.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
What should I avoid combining — and what's synergistic?
The most important thing here isn't a drug interaction — it's evidence quality: Dihexa rests on a retracted paper, and the Khavinson peptides lack Western replication. Go in knowing the data is early. Avoid in pregnancy, and loop in a clinician if you're on other neurological medications.
How can I buy this?
We don't have a verified affiliate source for Cognitive Peptides Cluster yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Why this is a cluster article
These three peptides — Dihexa, Pinealon, Cortagen — sit in the second tier of the cognitive cluster. The evidence base is thinner, more concentrated within single research groups, and in one case has a serious integrity problem we have to surface up front. None of them is in Alyve’s launch catalog. The reason they get a cluster article rather than three separate deep-dives: each is interesting enough to know about, but none has the evidence depth that Semax or Selank carries. Treat this as the “what else is out there in cognitive peptides, and what’s the honest read” reference.
The honest framing for the whole cluster:
- Dihexa has a major retraction in its foundational paper. We lead with that.
- Pinealon + Cortagen are part of the Khavinson bioregulator family — a 50-year Russian short-peptide research program that’s heterodox by Western molecular-biology standards but has a sustained, internally-consistent evidence record. We capture both sides honestly.
The Khavinson framework — context for Pinealon and Cortagen
Before the per-peptide sections, the framework is worth knowing because Pinealon and Cortagen both sit inside it.
Origin: 1970s Soviet military-medicine research at the Military Medical Academy in Leningrad. Researchers extracted tissue-specific peptide fractions from organs (thymus, pineal, cortex, etc.) and observed bioactive effects when re-administered. Vladimir Khavinson became the program’s central figure; the post-1991 St. Petersburg Institute of Bioregulation and Gerontology became its institutional home.
Theoretical claim: Short peptides (2-4 amino acids) cross cell + nuclear membranes → bind specific DNA promoter regions → modulate transcription in a tissue-specific way. The sequence of each peptide is claimed to reproduce a fragment originally extracted from the target organ tissue — Pinealon for brain/pineal, Cortagen for cortex, Epithalon for pineal/telomerase (Epithalon when built), Thymalin for thymus, etc.
Western reception is split. The conventional Western position: preclinical-only, single-research-group, weak methodology, mechanism heterodox. The Russian/Eastern European position: 50-year sustained research program with consistent reported outcomes and several peptides (Cortexin, Thymalin) approved for clinical use in Russia. OHM’s lean per doctrine: report both perspectives honestly; don’t dismiss the body of work, don’t overclaim it. The mechanism is interesting; the lack of Western RCT replication is a real evidence gap; both are true.
Dihexa
What it is
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic six-amino-acid peptide derivative of angiotensin IV — the C-terminal fragment of angiotensin II. It was developed by Dr. Joseph Harding’s lab at Washington State University around 2011. The lipophilic, BBB-crossing structure makes it one of the rare peptides that’s actually orally active.
Mechanism (claimed)
Dihexa is claimed to bind hepatocyte growth factor (HGF) with very high affinity and to potentiate HGF activity at its receptor c-Met → drive synaptogenesis (the physical formation of new synaptic connections between neurons). This puts it in a different category from the BDNF-upregulating peptides (Semax, Selank) — Dihexa is claimed to build new neural architecture rather than upregulate the brain’s existing repair signaling.
That’s the claim. The integrity status of the claim is the next section.
🚨 The retraction — and what it means
The foundational paper has been retracted.
- Benoist CC, Kawas LH, et al. (Harding group) — Journal of Pharmacology and Experimental Therapeutics 2014, 351(2):390-402 — PMID 25187433 — RETRACTED 2025 (retraction PMID 40312093). Expression of Concern issued September 2021.
This is the paper that established Dihexa’s claimed HGF/c-Met mechanism and the widely-circulated claim that “Dihexa is seven orders of magnitude more potent than BDNF.” That number — and the entire mechanism case it rests on — traces back to this single retracted paper. The retraction was preceded by an Expression of Concern in 2021, then formalized in 2025.
What this means in practice: the marketing claim that Dihexa is the most potent nootropic ever discovered is built on a foundation that’s been pulled out from under it. Every peptide-info site and forum that still reproduces the “7 orders of magnitude vs BDNF” line is reproducing a claim from a retracted study. Most of those sites have not updated. OHM’s position: lead with the retraction. Being the credible source that reports the integrity story honestly is the play here, not amplifying the hype.
The follow-up Dihexa literature (also primarily from the Harding group) what’s still standing post-retraction. Beyond Benoist 2014, there are zero completed human trials for Dihexa.
Dosing (community, anecdotal — no validated protocol)
- Oral: 8-45 mg/day (wide community range).
- Subcutaneous: 2-5 mg/day.
- Cycle: No validated cycle length.
These numbers come from forum convergence, not from clinical trials. There is no validated dose-finding study for Dihexa in humans.
Safety + AE profile
The safety database is essentially empty. This is the most important caveat — Dihexa is billed as “the most potent nootropic ever discovered” but the underlying mechanism paper is retracted and there is no human safety record to speak of.
Theoretical concerns worth taking seriously:
- The HGF/c-Met pathway is also a driver in multiple cancers — uncontrolled stimulation is a biologically plausible cancer-promotion risk oncology literature. Hard contraindication for active malignancy or cancer history.
- Angiotensin-pathway off-target effects on the cardiovascular system — unknown.
Sequencing rule (the part Jones gets right, independent of the mechanism story)
Even setting aside the foundational mechanism retraction, the operational rule for ANY synaptogenic compound is the same: clear neuroinflammation first, then add the synaptogenic compound — never the reverse. Jones (2026): “A brain running hot with neuroinflammation isn’t going to respond the way that a clean brain would. You’re wasting the compounds and potentially masking what’s actually driving the cognitive issues. Clear the inflammation, get mitochondria functioning, hormones optimized — and then maybe you lay your Dihexa down.” This is the same logical pattern as the SS-31 → MOTS-c sequencing rule and is good general practice for layered cognitive protocols regardless of which specific synaptogenic compound is at the end of the chain. (Worth noting: Jones’s video on Dihexa positions it as “among the most compelling preclinical results in the entire neuropeptide space” and does not surface the Benoist 2014 retraction. OHM’s position, anchored in the retraction record above, stays the more skeptical read of the mechanism case while still preserving the useful sequencing wisdom.)
Status
- Regulatory: Not FDA-approved. Not a controlled substance. PCAC review July 23-24, 2026: Dihexa is one of 12 peptides going to the FDA’s Pharmacy Compounding Advisory Committee for 503A re-evaluation. Even a positive vote would clear it for compounding only — not full FDA drug approval — and OHM’s position remains that the mechanism retraction + empty human safety database make Dihexa a low-confidence compound regardless of the PCAC outcome.
- Alyve product: Not in Alyve’s current launch catalog: flagged as a roadmap candidate (though, given the retraction + empty human safety database + HGF/c-Met cancer concern, Dihexa is a low-priority candidate at best; the supply-chain trust story works only if the molecule itself is one we’re confident in).
- OHM grade: C/yellow.
Pinealon (Glu-Asp-Arg / EDR)
What it is
Pinealon is a synthetic Khavinson tripeptide: sequence Glu-Asp-Arg (EDR). Molecular formula C₁₅H₂₆N₆O₈, molecular weight 418.41 g/mol. Developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology as part of the broader Khavinson peptide-bioregulator program.
Mechanism (claimed — Khavinson framework)
A triple-mechanism case:
- PEPT2 oral transport — Pinealon is small enough to cross intestinal, renal, and brain membranes via the PEPT2 peptide transporter. Genuinely orally bioavailable — rare for a peptide and one of Pinealon’s distinguishing features bioavailability magnitude.
- DNA regulatory binding — the Khavinson core claim. Pinealon is said to directly bind DNA promoter regions in neuronal nuclei and modulate gene expression. Mechanism is heterodox by Western molecular-biology standards and under-replicated outside the Khavinson group independent replication.
- Antioxidant + serotonergic modulation — measured oxidative-stress reduction and serotonin-pathway stimulation in brain cortex in animal models.
Evidence
Entirely Khavinson-group + collaborators. No Western RCTs. The publication record is real and sustained over a decade-plus within the Russian ecosystem — that’s the honest both-sides framing.
- Khavinson et al. 2011 Rejuvenation Research 14(5) — cognitive support in offspring models.
- Arutjunyan et al. 2012 Int J Clin Exp Med 5(2) — prenatal neuroprotection.
- Khavinson et al. 2014 Bull Exp Biol Med 157(1) — cell renovation mechanisms.
- Karantysh et al. 2020 Neurochemical Journal 14(3) — learning + glutamatergic gene expression in diabetic aging models.
- Khavinson et al. 2020 Molecules — gene expression + protein synthesis regulation.
Dosing
Both oral and injectable are validated within the Khavinson protocols — Pinealon’s oral viability is genuinely unusual for a peptide and is one of its main practical features.
| Route | Dose | Cycle | Frequency |
|---|---|---|---|
| Oral | 20 mg/day (typically 2× 10 mg capsules), morning, empty stomach | 20-30 consecutive days | 2-3 cycles/year |
| Subcutaneous | 5-10 mg/day; rotate injection sites | 10-20 consecutive days | 2-3 cycles/year |
Persistence claim: Khavinson’s framework claims benefits continue 2-3 months post-cycle — the “epigenetic-like persistence” the framework asserts for all Khavinson bioregulators (the basis for the cycle/rest pattern rather than continuous dosing) magnitude + duration in independent studies.
Side effects + caveats
- Mild and uncommon: Headache (early days), sleep disturbance with evening dosing (dose AM only), mild GI upset on the oral route, injection-site reactions.
- “No serious AEs reported in published Russian research across a decade+” — but this is Russian-source pharmacovigilance only; long-term Western safety data doesn’t exist.
- Contraindications cited in the Russian protocols: Pregnancy, breastfeeding, age <18, active seizure disorders, concurrent serotonergic medications (SSRIs, etc.).
A surprising real-world signal — Pinealon for SLEEP (not its primary positioning)
External real-world data point (2026-06-16, Ryan Humiston, fitness creator). Humiston tested three peptides head-to-head for sleep effects in a self-protocol — DSIP (positioned as a sleep peptide; null for him), Epithalon (positioned partly on nocturnal-melatonin upregulation; null for him on sleep), and Pinealon (positioned as a neuroprotective antioxidant, not primarily as a sleep peptide). Pinealon was the surprise winner.: “Oddly enough, the one I saw the most benefit from was Pinealon, which is actually more of a neuroprotective antioxidant… I woke up and I felt almost rested. And I’m somebody who has sleep apnea. I wake up to the slightest of sound. And I sleep with a dog who’s paralyzed and farts in his sleep, and still I slept better. So if you’re going to try one, that’s the one.”
That his baseline is degraded (self-reported sleep apnea, light sleeper) strengthens the signal — he’s a hard person to move on sleep quality. The framework explanation is plausible: Pinealon’s antioxidant + serotonergic-modulation effects could plausibly secondary into sleep-quality improvement via cortical calming + oxidative-stress reduction during sleep, even though the peptide isn’t sold or studied as a primary sleep agent. Cross-link to DSIP (the “intuitive” sleep peptide that didn’t help one tested user) and Epithalon (the longevity peptide whose claimed nocturnal-melatonin effect didn’t translate to subjective sleep improvement for the same user).
Honest framing: this is a single-user n=1 anecdote, not a sleep trial — it does NOT establish Pinealon as a sleep peptide. But it’s the kind of real-world signal that warrants logging because (a) it ran a head-to-head test against the two peptides most often recommended for sleep, (b) it came from a user with a difficult baseline, and © the mechanism plausibly supports the observation as a secondary effect. Worth flagging when readers ask which Khavinson short peptide to try first for sleep quality — and worth running as a deliberate trial alongside the standard sleep-foundation work (light hygiene, magnesium, no late caffeine, etc.).
Status
- Regulatory: Not FDA-approved.
- Counterfeiting risk — significant for this category specifically; verified-COA vendor matters more for Khavinson-family peptides than for most others because Russian-source counterfeit product is the dominant gray-market failure mode.
- Alyve product: Not in Alyve’s current launch catalog: flagged as a roadmap candidate.
- OHM grade: C/green.
Cortagen (Ala-Glu-Asp-Pro / AEDP)
What it is
Cortagen is a synthetic Khavinson tetrapeptide: sequence Ala-Glu-Asp-Pro (AEDP). One of approximately 15 organ-targeted peptides in the Khavinson bioregulator family (alongside Pinealon, Epithalon, Vilon, Thymalin, Cortexin, etc.). Same Khavinson group / St. Petersburg Institute lineage.
Mechanism (claimed)
Same Khavinson framework: cross cell and nuclear membranes, bind specific DNA promoter sequences, modulate transcription in a tissue-specific way. Cortagen’s tissue specificity is cortical neurons.
Operational distinction vs. Semax / Selank:
- Semax → acute receptor-mediated signaling (MC4/MC3 → BDNF/NGF transcription; fast onset, days).
- Selank → acute multi-pathway modulation (BDNF + enkephalin + monoamine; fast onset, days).
- Cortagen → claimed gene-expression modulation → effects develop over a 10-20 day cycle and are claimed to persist 2-3 months after the cycle ends. Slow-onset, long-tail mechanism if the Khavinson framework holds.
Evidence
- Animal data: Rodent + aging-rat studies showing improved Morris water maze performance, increased hippocampal BDNF expression, oxidative neuroprotection PMIDs.
- Human data: Russian post-stroke clinical studies showing cognitive improvement — lack blinded design; methodologically weak by Western RCT standards. The clinical signal is interesting; the trial design is not what a Western reviewer would accept as proof.
- Key references: Khavinson + Kuznik Peptide Bioregulators monograph (2014); Khavinson Peptides and Ageing (PubMed).
- No Western RCTs.
Dosing
Cortagen has more route variety than most peptides — it’s available as SubQ injection, IM injection, sublingual drops, and oral capsule, with different protocols for each:
| Context | Dose | Route | Duration | Frequency |
|---|---|---|---|---|
| Cognitive / nootropic | 200-400 mcg | SubQ | 10-20 days | 2-3×/year |
| Post-TBI / post-stroke (Russian clinical) | 2-10 mg | IM | 5-10 days | Per neurologist |
| Sublingual retail | 3-4 drops | SL | 30 days | 3×/year |
| Oral capsule retail | 2 daily | PO | 30 days cycled | 3-4×/year |
Storage: Lyophilized at -20°C is stable 2+ years; reconstituted (bacteriostatic water with 0.9% benzyl alcohol) refrigerate at 2-8°C and discard at 28 days.
Side effects + caveats
- Infrequent local injection-site reactions; transient mild headache early in the cycle.
- No serious AEs documented at standard doses in the Russian literature.
- Counterfeiting risk is real — flagged across multiple sources for this peptide specifically. Verified-COA vendor is essential.
- Long-term repeated-cycle safety in humans is not characterized in Western pharmacovigilance.
Status
- Regulatory: Not FDA-approved.
- Alyve product: Not in Alyve’s current launch catalog: flagged as a roadmap candidate.
- OHM grade: C/green.
Cluster comparison
| Property | Dihexa | Pinealon | Cortagen |
|---|---|---|---|
| Class | Angiotensin IV analog (synthetic) | Khavinson tripeptide | Khavinson tetrapeptide |
| Sequence | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Glu-Asp-Arg (EDR) | Ala-Glu-Asp-Pro (AEDP) |
| Origin | Joseph Harding, WSU, ~2011 | Khavinson group, St. Petersburg, ~1990s-2000s | Khavinson group, St. Petersburg, ~1990s-2000s |
| Mechanism (claimed) | HGF / c-Met → synaptogenesis | DNA promoter binding + PEPT2 oral transport + antioxidant | DNA promoter binding (cortical tissue-specific) |
| Onset | Days (rodent data) | Slow (10-20 day cycle, 2-3 month tail claimed) | Slow (10-20 day cycle, 2-3 month tail claimed) |
| Route | Oral or SubQ | Oral or SubQ (oral validated — rare for a peptide) | SubQ / IM / SL / oral |
| Dose | 2-5 mg SubQ; 8-45 mg oral (community) | 20 mg oral; 5-10 mg SubQ (Khavinson protocol) | 200-400 mcg SubQ (cognitive) |
| 🚨 Foundational paper status | Benoist 2014 RETRACTED 2025 | Multiple Khavinson group papers standing | Multiple Khavinson group papers standing |
| Hard contraindication | Active cancer (HGF/c-Met risk) | Pregnancy, seizures, concurrent SSRIs | Pregnancy; counterfeit risk |
| Human trial status | Zero Western trials; retracted foundational paper | Zero Western RCTs; sustained Russian preclinical record | Zero Western RCTs; unblinded Russian clinical |
| Alyve catalog | Not in launch 15 — roadmap candidate (low priority) | Not in launch 15 — roadmap candidate | Not in launch 15 — roadmap candidate |
| OHM grade | C/yellow | C/green | C/green |
The Alyve story
None of the three is in Alyve’s current launch catalog: all three are flagged as roadmap candidates, with different calculus for each.
The broader Alyve trust story still anchors the conversation — US-manufactured + third-party Freedom Diagnostics COAs + >99% purity verified across the launch catalog + identity-confirmed by HPLC-UV + LC-MS. For the Khavinson-family peptides especially, that supply-chain story matters disproportionately: counterfeit Pinealon and Cortagen are the dominant gray-market failure mode, and the typical buyer of Russian-school peptides has no easy way to verify what they’re getting. A verified-COA vendor with US manufacturing isn’t a luxury for this category — it’s the whole point of buying from a vendor at all rather than from a forum link.
For Dihexa specifically, the retraction + empty human safety database + HGF/c-Met cancer concern make it a low-priority roadmap candidate. The supply-chain trust story only works if the underlying molecule is one we’re confident is worth supplying.
Use code OHM-15 for 15% off: Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. While the cognitive-cluster roadmap peptides aren’t live yet, the same bulk logic powers the SKUs that are: a 3-vial purchase of BPC-157, GHK-Cu, or TB-500 crosses the bulk threshold and gives you a meaningful protocol block at the highest discount tier.
Sources
- primary source for the entire cluster, including the Benoist 2014 retraction (PMID 25187433 → retraction PMID 40312093), the Khavinson framework context, mechanism claims, dosing protocols, and the comparison table.
- baseline grading for all three.
- Cross-references:, (for the broader Russian-school cognitive cluster), (Epithalon — sister Khavinson peptide).
Related: Semax · Selank · Glutathione · BPC-157 · GHK-Cu · MOTS-c.
Sources & references
- primary source for the entire cluster, including the Benoist 2014 retraction (PMID 25187433 → retraction PMID 40312093), the Khavinson framework context, mechanism claims, dosing protocols, and the comparison table.
- baseline grading for all three.
- Cross-references:, (for the broader Russian-school cognitive cluster), (Epithalon — sister Khavinson peptide).
Related: Semax · Selank · Glutathione · BPC-157 · GHK-Cu · MOTS-c.